NBDC Research ID: hum0372.v1
SUMMARY
Aims: To elucidate the genetic predisposition to metabolic syndrome-related diseases such as diabetes and the genetic predisposition to reactivity and side effects of diabetes drugs in Japanese people, and to apply this to the prevention of diabetes and personalized medicine.
Methods: We profiled serum metabolites of persons with type 2 diabetes (T2D) with or without diabetic complications using a comprehensive non-targeted metabolomics approach with mass spectrometry. The abundance of the 364 serum metabolites was compared between the T2D patients with multiple complications (N = 141) and those without any complications (N = 159), then calculated the summary statistics.
Participants/Materials: T2D
| Dataset ID | Type of Data | Criteria | Release Date |
|---|---|---|---|
| JGAS000572 | the abundance of the 364 serum metabolites | Controlled-access (Type I) | 2022/11/22 |
| MTBKS213, MTBKS214 | the summary statistics | Unrestricted-access | 2022/11/22 |
* Data users need to apply an application for Using NBDC Human Data to reach the Controlled-access Data. Learn more
*When the research results including the data which were downloaded from MataboBank, are published or presented somewhere, the data user must refer the papers which are related to the data, or include in the acknowledgment. Learn more
MOLECULAR DATA
JGAS000572 / MTBKS213 / MTBKS214
| Participants/Materials |
T2D without diabetic complications (ICD10: E11): 159 cases T2D with both diabetic kidney disease and diabetic retinopathy (ICD10: E11): 141 cases |
| Targets | metabolome |
| Target Loci for Capture Methods | - |
| Platform |
Agilent Technologies [Agilent CE system equipped with an Agilent 6210 TOFMS, Agilent 1100 isocratic HPLC pump] Agilent Technologies [Agilent LC System equipped with an Agilent 6230 TOFMS] |
| Source | Serum |
| Cell Lines | - |
| Measurement Method |
Agilent Technologies [Agilent CE system equipped with an Agilent 6210 TOFMS, Agilent 1100 isocratic HPLC pump] Agilent Technologies [Agilent LC System equipped with an Agilent 6230 TOFMS] |
| Measurement Conditions (Parameters) | - |
| Noise reduction & Data correction | - |
| Annotation | - |
| Quantification Methods (software) | - |
| Metabolic biomarkers | 364 serum metabolites |
| Japanese Genotype-phenotype Archive Dataset ID | JGAD000698 |
| MetaboBank Accession ID |
CE-MS: MTBKS213 LC-MS: MTBKS214 |
| Total Data Volume |
JGAD000698: 2.1 MB (txt) MTBKS213 / MTBKS214: 39 KB (tsv) |
| Comments (Policies) | NBDC policy |
DATA PROVIDER
Principal Investigator: Toshimasa Yamauchi 1 / Takashi Kadowaki 1,2 / Yukinori Okada 3
Affiliation: 1. Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo
2. Toranomon Hospital
3. Department of Statistical Genetics, Graduate School of Medicine, Osaka University
Project / Group Name: Social implementation of next-generation precision medicine from Japan based on comprehensive analysis of genetic and environmental factors of diabetes
Funds / Grants (Research Project Number):
| Name | Title | Project Number |
|---|---|---|
| Platform Program for Promotion of Genome Medicine, Japan Agency for Medical Research and Development (AMED) | Realization of next-generation precision medicine from Japan based on comprehensive analysis of genetic and environmental factors of diabetes | JP20km0405202 |
| Platform Program for Promotion of Genome Medicine, Japan Agency for Medical Research and Development (AMED) | Social implementation of next-generation precision medicine from Japan based on comprehensive analysis of genetic and environmental factors of diabetes | JP21tm0424218 |
PUBLICATIONS
| Title | DOI | Dataset ID | |
|---|---|---|---|
| 1 | Identification of serum metabolome signatures associated with retinal and renal complications of type 2 diabetes | doi: 10.1038/s43856-022-00231-3 | JGAD000698 MTBKS213 MTBK214 |
| 2 |
USRES (Controlled-access Data)
| Principal Investigator | Affiliation | Country/Region | Research Title | Data in Use (Dataset ID) | Period of Data Use |
|---|---|---|---|---|---|
